{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:09:26Z","timestamp":1792796966940,"version":"4.5.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Previous guidelines for the treatment of immune thrombocytopenia (ITP) have traditionally focused on a dichotomy between pediatric and adult ITP. Adolescents and young adults (AYAs) do not neatly fit into either the pediatric or adult ITP group. A deeper understanding of ITP\u2019s natural history, risk factors for chronicity, and outcomes in AYAs is a crucial first step toward developing tailored treatment algorithms. Such data could form the basis for recommendations targeting this underrepresented yet clinically distinct population. Ultimately, age-adapted trials may improve long-term outcomes, reduce toxicity, and enhance quality of life for AYAs with ITP. The AYAs collaboration\u2014drawing on data from the Pediatric and Adult Registry on Chronic ITP (PARC-ITP), Registre Midi- Pyr\u00e9n\u00e9en-France (CARMEN-France) adult registry in Toulouse, and the National Prospective Cohort for Children with Chronic Autoimmune Cytopenia (OBS\u2019CEREVANCE) in Bordeaux, France\u2014aims to address the information gap in AYAs with ITP. To date, four analyses have been undertaken (using data from 2004 to 2021), each addressing the major clinical aspects of ITP in patients aged 12\u201325\u202fyears: (1) newly diagnosed ITP, (2) chronic disease, (3) refractory courses, and (4) secondary (sITP) forms.<\/jats:p>","DOI":"10.3389\/fmed.2025.1553936","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T03:22:07Z","timestamp":1742959327000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Immune thrombocytopenia in adolescents and young adults"],"prefix":"10.3389","volume":"12","author":[{"given":"Alexandra","family":"Schifferli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/jayao.2016.0012","article-title":"What are the unmet needs and care experiences of adolescents and young adults with cancer? A systematic review","volume":"6","author":"Bibby","year":"2017","journal-title":"J Adolesc Young Adult Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1634\/theoncologist.2014-0265","article-title":"Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop","volume":"20","author":"Nass","year":"2015","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2014-04-570127","article-title":"Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis","volume":"124","author":"Heitink-Poll\u00e9","year":"2014","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1067\/S0022-3476(03)00535-3","article-title":"A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the intercontinental childhood ITP study group","volume":"143","author":"K\u00fchne","year":"2003","journal-title":"J Pediatr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/pbc.21872","article-title":"Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina","volume":"52","author":"Donato","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/bjh.15070","article-title":"Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopaenia","volume":"184","author":"G\u00f3mez Almaguer","year":"2019","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/bjh.16327","article-title":"Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia","volume":"189","author":"Zhang","year":"2020","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/bjh.19074","article-title":"Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: the iROM study","volume":"203","author":"Schifferli","year":"2023","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.282524","article-title":"Adolescents and young adults with newly diagnosed primary immune thrombocytopenia","volume":"108","author":"Schifferli","year":"2023","journal-title":"Haematologica"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.1182\/bloodadvances.2024014381","article-title":"Sustained remission at long term follow-up in adolescents and young adults with chronic primary immune thrombocytopenia","volume":"8","author":"Schifferli","year":"2024","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/bjh.19081","article-title":"Chronic refractory immune thrombocytopenia in adolescents and young adults","volume":"203","author":"Schifferli","year":"2023","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1182\/blood-2024-200034","article-title":"Adolescents and young adults with secondary chronic immune thrombocytopenia: a Switzerland\/France collaboration project","volume":"144","author":"Schifferli","year":"2024","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1067\/mpd.2002.125909","article-title":"Idiopathic thrombocytopenic purpura diagnosed during the second decade of life","volume":"141","author":"Lowe","year":"2002","journal-title":"J Pediatr"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3324\/haematol.2013.103291","article-title":"Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration","volume":"99","author":"Bussel","year":"2014","journal-title":"Haematologica"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/bjh.16448","article-title":"Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years","volume":"189","author":"Ducassou","year":"2020","journal-title":"Br J Haematol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/bloodadvances.2020001446","article-title":"Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan","volume":"4","author":"Hato","year":"2020","journal-title":"Blood Adv"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s00277-017-3095-6","article-title":"Life-threatening bleeding episodes in primary immune thrombocytopenia: a single-center retrospective study of 169 inpatients","volume":"96","author":"Tsuda","year":"2017","journal-title":"Ann Hematol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1182\/blood-2009-04-215525","article-title":"Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases","volume":"114","author":"Psaila","year":"2009","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/00043426-200308000-00017","article-title":"Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis","volume":"25","author":"Butros","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajh.25086","article-title":"A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up","volume":"93","author":"Schifferli","year":"2018","journal-title":"Am J Hematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1651-2227.2012.02671.x","article-title":"Duration and morbidity of chronic immune thrombocytopenic purpura in children: five-year follow-up of a Nordic cohort","volume":"101","author":"Rosth\u00f8j","year":"2012","journal-title":"Acta Paediatr"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/pbc.20453","article-title":"Childhood ITP: 12 months follow-up data from the prospective registry I of the intercontinental childhood ITP study group (ICIS)","volume":"46","author":"Imbach","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0031-3955(05)70431-4","article-title":"Current controversies in the management of idiopathic thrombocytopenic purpura during childhood","volume":"43","author":"Medeiros","year":"1996","journal-title":"Pediatr Clin N Am"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1097\/00043426-200312001-00007","article-title":"Childhood chronic immune thrombocytopenic Purpura: unresolved issues","volume":"25","author":"Blanchette","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5045\/br.2014.49.3.187","article-title":"Natural course of childhood chronic immune thrombocytopenia using the revised terminology and definitions of the international working group: a single center experience","volume":"49","author":"Shim","year":"2014","journal-title":"Blood Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3349\/ymj.2016.57.1.127","article-title":"High remission rate of chronic immune thrombocytopenia in children: result of 20-year follow-up","volume":"57","author":"Kim","year":"2016","journal-title":"Yonsei Med J"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/pbc.20982","article-title":"Splenectomy and spontaneous remission in children with chronic idiopathic thrombocytopenic purpura","volume":"47","author":"Donato","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/00043426-200411000-00007","article-title":"Long-term outcome of chronic idiopathic thrombocytopenic purpura in children","volume":"26","author":"Jayabose","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e26736","DOI":"10.1002\/pbc.26736","article-title":"Predictors of remission in children with newly diagnosed immune thrombocytopenia: data from the intercontinental cooperative ITP study group registry II participants","volume":"65","author":"Bennett","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e26389","DOI":"10.1002\/pbc.26389","article-title":"Childhood immune thrombocytopenia: a nationwide cohort study on condition management and outcomes","volume":"64","author":"Grimaldi-Bensouda","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1182\/blood.V110.11.3917.3917","article-title":"Less chronic ITP after IVIG for acute childhood ITP? A matched pairs analysis from registry I of the intercontinental ITP study group (ICIS)","volume":"110","author":"Tamminga","year":"2007","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/pbc.22346","article-title":"Outcome of chronic idiopathic thrombocytopenic purpura in children: chronic ITP in children","volume":"54","author":"Bansal","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.1651-2227.1994.tb13175.x","article-title":"Chronic childhood idiopathic thrombocytopenia purpura: long-term follow-up","volume":"83","author":"Tamary","year":"1994","journal-title":"Acta Paediatr"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.anpedi.2010.09.035","article-title":"What is the prognosis of chronic immune thrombocytopenia?","volume":"74","author":"Calleja Gero","year":"2011","journal-title":"An Pediatr (Barc)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1182\/blood-2022-157723","article-title":"Multirefractory primary immune thrombocytopenia in adults: prevalence and burden. Results from the CARMEN-France registry","volume":"140","author":"Moulis","year":"2022","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1182\/blood.2019003599","article-title":"Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment","volume":"135","author":"Miltiadous","year":"2020","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1182\/blood-2016-03-704734","article-title":"Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia","volume":"128","author":"Mah\u00e9vas","year":"2016","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1046\/j.1365-2141.2002.03709.x","article-title":"High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura","volume":"118","author":"Levy","year":"2002","journal-title":"Br J Haematol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/ajh.24434","article-title":"Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia","volume":"91","author":"Chapin","year":"2016","journal-title":"Am J Hematol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.3324\/haematol.2019.226688","article-title":"Blood transcriptome and clonal T cell correlates of response and nonresponse to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia","volume":"105","author":"Zhang","year":"2020","journal-title":"Haematologica"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1046\/j.1365-2249.2003.02239.x","article-title":"T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy","volume":"133","author":"Fogarty","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ajh.22211","article-title":"Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIb\u03b1 antibodies","volume":"87","author":"Zeng","year":"2012","journal-title":"Am J Hematol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1182\/blood-2005-06-009761","article-title":"Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies","volume":"108","author":"Webster","year":"2006","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1182\/bloodadvances.2017010942","article-title":"Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP registry","volume":"1","author":"Arnold","year":"2017","journal-title":"Blood Adv"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000529662","article-title":"Expert report on immune thrombocytopenia: current diagnostics and treatment-recommendations from an expert group from Austria, Germany, and Switzerland","volume":"46","author":"Matzdorff","year":"2023","journal-title":"Oncol Res Treat"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e27260","DOI":"10.1002\/pbc.27260","article-title":"Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults","volume":"65","author":"Rotz","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"10760296211059813","DOI":"10.1177\/10760296211059813","article-title":"Chronic refractory immune thrombocytopenia is associated with variants in immune genes","volume":"27","author":"Zhao","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/bjh.19073","article-title":"Paediatric-onset Evans syndrome: breaking away from refractory immune thrombocytopenia","volume":"203","author":"Aladjidi","year":"2023","journal-title":"Br J Haematol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2018-11-887141","article-title":"Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes","volume":"134","author":"Hadjadj","year":"2019","journal-title":"Blood"},{"key":"ref57","author":"Phillips","year":""},{"key":"ref58","year":""},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/pbc.25644","article-title":"Sports participation in children and adolescents with immune thrombocytopenia (ITP)","volume":"62","author":"Kumar","year":"2015","journal-title":"Pediatr Blood Cancer"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1553936\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T03:22:09Z","timestamp":1742959329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1553936\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":59,"alternative-id":["10.3389\/fmed.2025.1553936"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1553936","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"article-number":"1553936"}}